MCID: CRC006
MIFTS: 52

Carcinoid Syndrome malady

Categories: Rare diseases, Endocrine diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Carcinoid Syndrome

Aliases & Descriptions for Carcinoid Syndrome:

Name: Carcinoid Syndrome 50
Carcinoid Tumor 50 29 69
Carcinoid Tumor No Icd-O Subtype 69
Malignant Carcinoid Syndrome 69
Carcinoid Tumor Syndrome 50
Neuroendocrine Tumors 69
Neuroendocrine Tumor 50
Carcinoid Tumors 41

Classifications:



External Ids:

ICD10 33 E34.0

Summaries for Carcinoid Syndrome

NIH Rare Diseases : 50 carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. in later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure. the condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms. last updated: 9/25/2015

MalaCards based summary : Carcinoid Syndrome, also known as carcinoid tumor, is related to zollinger-ellison syndrome and pheochromocytoma. An important gene associated with Carcinoid Syndrome is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and HIF-1 signaling pathway. The drugs Paclitaxel and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and liver, and related phenotypes are growth/size/body region and homeostasis/metabolism

MedlinePlus : 41 carcinoid tumors are rare, slow-growing cancers. they usually start in the lining of the digestive tract or in the lungs. they grow slowly and don't produce symptoms in the early stages. as a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. in later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. the syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. surgery is the main treatment for carcinoid tumors. if they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 71 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
id Related Disease Score Top Affiliating Genes
1 zollinger-ellison syndrome 29.7 CHGA ENO2 SYP
2 pheochromocytoma 28.9 CALCA CHGA ENO2 MEN1 NPY SST
3 duodenal carcinoid syndrome 11.8
4 carcinoid tumors, intestinal 11.3
5 pellagra 11.1
6 serotonin syndrome 10.7
7 peroneal nerve paralysis 10.3 CHGA SYP
8 secondary syphilis 10.3 CHGA SST
9 brain edema 10.3 CHGA SST
10 brain stem ependymoma 10.3 CHGA SYP
11 wells-jankovic syndrome 10.3 CALCA SST
12 non specific chronic endometritis 10.3 CHGA SYP
13 extrahepatic biliary papillomatosis 10.3 CHGA SYP
14 epithelioid malignant peripheral nerve sheath tumor 10.3 CHGA SYP
15 postgastrectomy syndrome 10.3 SST SYP
16 cartilage cancer 10.3 CHGA SYP
17 villous adenocarcinoma 10.3 CHGA SYP
18 jejunal neuroendocrine tumor 10.3 CHGA SYP
19 renal pelvis adenocarcinoma 10.3 CHGA SYP
20 vaginal adenoma 10.3 IGF1 SST
21 neuritis 10.3 SST SYP
22 barre-lieou syndrome 10.3 CHGA SYP
23 bone dysplasia azouz type 10.3 CHGA SST SYP
24 microinvasive cervical squamous cell carcinoma 10.2 CHGA SYP
25 testicular trophoblastic tumor 10.2 CALCA CHGA SYP
26 adult ependymoblastoma 10.2 CALCA CHGA MEN1
27 acute pyelonephritis 10.2 CHGA MEN1 SST
28 early-onset parkinson disease 10.2 MEN1 SST SYP
29 maturity-onset diabetes of the young, type 13 10.2 CHGA MEN1 SST
30 dysgerminoma of ovary 10.2 CHGA MEN1 SYP
31 tabes dorsalis 10.2 MEN1 SST SYP
32 non-syndromic x-linked intellectual disability 10.2 CHGA NPY SST
33 aneurysm 10.2 CALCA CHGA MEN1
34 gastric duplication cysts 10.2 CHGA SYP
35 parathyroid carcinoma 10.2 CALCA CHGA MEN1
36 choline deficiency disease 10.2 NTS PYY SST
37 ischemic heart disease 10.2 CHGA MEN1 SST
38 tricuspid valve stenosis 10.2 NTS PYY SST
39 peripheral degeneration of cornea 10.2 NTS PYY SST
40 hepatitis 10.2
41 subserous uterine fibroid 10.2 CALCA CHGA MEN1
42 cerebellar hypoplasia with endosteal sclerosis 10.2 CALCA NPY
43 sm-ahnmd 10.2 CHGA ENO2
44 croup 10.2 IFNA2 SST
45 uterine ligament cancer 10.2 IGF1 MEN1 SST
46 infiltrating renal pelvis transitional cell carcinoma 10.2 ENO2 SYP
47 axial osteomalacia 10.2 CALCA IGF1 SST
48 gmppa-cdg 10.2 CHGA GHRH SST
49 skeletal-extraskeletal angiomatosis 10.2 ENO2 SYP
50 diffuse cutaneous mastocytosis 10.2 CHGA SYP

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

MGI Mouse Phenotypes related to Carcinoid Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.9 CHGA ENO2 GHRH HTR3A IGF1 MEN1
2 homeostasis/metabolism MP:0005376 9.65 CHGA GHRH HTR3A IGF1 MEN1 NPY
3 nervous system MP:0003631 9.36 NTS PYY SST SYP VEGFA ENO2

Drugs & Therapeutics for Carcinoid Syndrome

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 646)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
5
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
6
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83150-76-9 383414 6400441
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
8
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
9
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
10
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
11
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 159351-69-6 6442177
12
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
13
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
14
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
15
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
16
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53123-88-9 5284616 6436030 46835353
17
Aldesleukin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 85898-30-2, 110942-02-4
18
Vindesine Approved Phase 4 59917-39-4, 53643-48-4 40839
19
Pancrelipase Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
20
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
21
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
22
Gefitinib Approved, Investigational Phase 4,Phase 2 184475-35-2 123631
23
Etanercept Approved, Investigational Phase 4 185243-69-0
24
Cabergoline Approved Phase 4 81409-90-7 54746
25
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
26
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
27
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
28
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
29
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
30
Doxazosin Approved Phase 4 74191-85-8 3157
31
Aminolevulinic acid Approved Phase 4 106-60-5 137
32
Phenoxybenzamine Approved Phase 4 59-96-1 4768
33
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
34
Palbociclib Approved Phase 4,Phase 1,Phase 2 571190-30-2 11431660 5005498 5330286
35
Ceritinib Approved Phase 4,Phase 2 1032900-25-6
36
Olaparib Approved Phase 4 763113-22-0 23725625
37
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
38 triamcinolone acetonide Phase 4,Phase 2,Phase 3
39 pancreatin Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40
Lactitol Phase 4,Phase 1,Phase 2 585-86-4 3871
41 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
42
Erlotinib Hydrochloride Phase 4,Phase 2,Phase 1 183319-69-9 176871
43 Imatinib Mesylate Phase 4,Phase 2,Phase 3,Phase 1 123596
44 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 interferons Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
47 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
48 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Coagulants Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 2359)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
3 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
4 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
5 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
6 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4
7 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
8 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4
9 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
10 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
11 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
12 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
13 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
14 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
15 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
16 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
17 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4
18 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
19 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Recruiting NCT02626065 Phase 4
20 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4
21 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
22 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
23 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4
24 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4
25 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
26 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
27 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
28 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
29 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
30 Stereotactic Body Radiotherapy for Liver Tumors Active, not recruiting NCT01347333 Phase 4
31 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
32 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4
33 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4
34 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Active, not recruiting NCT01515189 Phase 4
35 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
36 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4
37 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4
38 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4
39 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
40 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
41 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3
42 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3
43 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3
44 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
45 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
46 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3
47 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3
48 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3
49 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
50 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Carcinoid Syndrome

Genetic tests related to Carcinoid Syndrome:

id Genetic test Affiliating Genes
1 Carcinoid Tumor 29

Anatomical Context for Carcinoid Syndrome

MalaCards organs/tissues related to Carcinoid Syndrome:

39
Heart, Lung, Liver, Skin, Testes, Colon, Pituitary

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 521)
id Title Authors Year
1
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. ( 27918724 )
2017
2
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. ( 26917486 )
2016
3
Carcinoid Syndrome-Induced Ventricular Tachycardia. ( 27088017 )
2016
4
Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female. ( 27895950 )
2016
5
Complications from carcinoid syndrome: review of the current evidence. ( 27594907 )
2016
6
Coronary artery spasm secondary to carcinoid syndrome. ( 27016533 )
2016
7
Carcinoid syndrome produced by an isolated metastase in femoral nerve from a midgut carcinoid tumor. ( 27026088 )
2016
8
Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea. ( 27519265 )
2016
9
The Great Deceiver: A Case of Central Sensitization Presenting as Carcinoid Syndrome. ( 27144900 )
2016
10
May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report. ( 27169982 )
2016
11
Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. ( 26877616 )
2016
12
Telotristat ethyl: a new option for the management of carcinoid syndrome. ( 27817224 )
2016
13
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. ( 27214300 )
2016
14
Emerging treatment options for carcinoid syndrome. ( 27673284 )
2016
15
Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach. ( 27041406 )
2016
16
Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): subgroup analysis of the ELECT study. ( 26431405 )
2015
17
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. ( 25636046 )
2015
18
Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. ( 26188238 )
2015
19
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. ( 26600780 )
2015
20
Primary neuroendocrine mediastinal tumor presenting with carcinoid syndrome and left supraclavicular lymphadenopathy. Clinico-radiological and pathological features. ( 26881686 )
2015
21
First-in-Human Transcatheter Pulmonic Valve Implantation Through a Tricuspid Valve Bioprosthesis to Treat Native Pulmonary Valve Regurgitation Caused by Carcinoid Syndrome. ( 26315750 )
2015
22
Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid Syndrome. ( 26470900 )
2015
23
Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. ( 25096997 )
2014
24
Duodenal carcinoid with carcinoid syndrome. ( 24414187 )
2014
25
Carcinoid syndrome caused by a serotonin-secreting pituitary tumour. ( 24174286 )
2014
26
Cognitive impairment associated with carcinoid syndrome. ( 23478527 )
2014
27
Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. ( 24676892 )
2014
28
Systemic mastocytosis mimicking carcinoid syndrome. ( 24711221 )
2014
29
Increased chromogranin A and carcinoid syndrome-like symptoms in a patient treated with duloxetine. ( 25100382 )
2014
30
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. ( 25012985 )
2014
31
Terminal ileal carcinoid tumor without hepatic or extrahepatic metastasis causing carcinoid syndrome. ( 23574858 )
2013
32
Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome. ( 23633214 )
2013
33
Early diffuse coronary artery spasm after heart valve surgery in the carcinoid syndrome. ( 23710535 )
2013
34
Primary neuroendocrine mediastinal tumor presenting with carcinoid syndrome and left supraclavicular lymphadenopathy: clinico-radiological and pathological features. ( 23771374 )
2013
35
Cutaneous scleroderma and malignant carcinoid syndrome. ( 23517363 )
2013
36
Hypoxia in a patient with carcinoid syndrome. ( 23994395 )
2013
37
Collision adenoma-carcinoid tumour of the colon complicated by carcinoid syndrome. ( 23023914 )
2012
38
Neuroendocrinology: Improved progression-free survival with everolimus plus octreotide in carcinoid syndrome. ( 22158198 )
2012
39
In patients with carcinoid syndrome undergoing valve replacement: will a biological valve have acceptable durability? ( 22691379 )
2012
40
5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. ( 22425693 )
2012
41
Acute inflammatory bowel disease complicating chronic alcoholism and mimicking carcinoid syndrome. ( 22949895 )
2012
42
The use of the Dermatology Life Quality Index in patients with malignant carcinoid syndrome. ( 21916881 )
2012
43
Control of carcinoid syndrome with everolimus. ( 21169474 )
2011
44
Carcinoid syndrome diagnosed by echocardiography. ( 19217173 )
2011
45
Carcinoid syndrome from small bowel endocrine carcinoma in the absence of hepatic metastasis. ( 21903639 )
2011
46
Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). ( 21585408 )
2011
47
Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection? ( 21493110 )
2011
48
Carcinoid syndrome and perioperative anesthetic considerations. ( 21663822 )
2011
49
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. ( 22119496 )
2011
50
MDCT imaging in malignant carcinoid syndrome. ( 21842275 )
2011

Variations for Carcinoid Syndrome

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.97 CALCA ENO2 NPY SYP
2 11.13 ENO2 IGF1 VEGFA
3 10.7 IGF1 SYP VEGFA
4 10.62 NPY PYY

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CALCA CHGA GHRH IFNA2 IGF1 NPY
2 neuronal cell body GO:0043025 9.56 CALCA ENO2 HTR3A SST
3 terminal bouton GO:0043195 9.33 CALCA GHRH SYP
4 extracellular space GO:0005615 9.32 CALCA CHGA ENO2 GHRH IFNA2 IGF1

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.65 CALCA NPY PYY
2 movement of cell or subcellular component GO:0006928 9.58 IGF1 NPY PYY
3 regulation of blood pressure GO:0008217 9.54 CALCA CHGA NPY
4 digestion GO:0007586 9.5 NPY PYY SST
5 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 GHRH IGF1
6 regulation of appetite GO:0032098 9.43 NPY PYY
7 response to heat GO:0009408 9.43 CALCA IGF1 SST
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.33 IFNA2 IGF1 VEGFA
9 feeding behavior GO:0007631 9.13 CALCA NPY PYY
10 cell-cell signaling GO:0007267 9.02 CALCA GHRH IFNA2 PYY SST

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.13 NPY NTS PYY
2 hormone activity GO:0005179 9.02 CALCA IGF1 NPY PYY SST

Sources for Carcinoid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....